Dr. Helena Fischer • May 13, 2026 • Health

RSV Prevention in Newborns: How Maternal Vaccination and Infant Immunization Stack Up

Respiratory syncytial virus (RSV) remains one of the most common causes of severe respiratory illness in infants worldwide, with nearly 100,000 hospitalizations annually in the U.S. Alone. But two promising strategies—maternal vaccination with RSVpreF and infant immunization with nirsevimab—are now offering new hope. A landmark interim analysis published in Pediatrics compares these approaches for the first time, revealing how they might be used together to protect the most vulnerable newborns.

The study, which has sparked debate among pediatric experts, raises critical questions: Can maternal vaccination and infant immunization be combined for maximum protection? What are the practical implications for parents and healthcare systems? And how might these findings reshape global RSV prevention strategies?

As a physician and health journalist, I’ll break down what we know so far—what the data shows, what the experts are saying and what it means for families preparing for the next RSV season.

Two Approaches, One Goal: Preventing RSV Hospitalizations

RSV has long been a silent epidemic, striking hardest in the first months of life. The disease can lead to bronchiolitis or pneumonia, often requiring hospitalization. Until recently, prevention options were limited to supportive care. Now, two tools have emerged:

• Maternal RSVpreF vaccination: Administered during pregnancy, this vaccine helps mothers pass protective antibodies to their newborns through the placenta. Approved in 2023, it was designed to reduce the risk of severe RSV disease in infants too young for other vaccines.
• Infant nirsevimab: A monoclonal antibody given as a single injection to infants during their first RSV season, nirsevimab provides immediate, short-term protection against severe disease.

Both strategies have shown promise in clinical trials, but until now, no study had directly compared their effectiveness—or explored whether combining them could offer even greater protection. That’s where this new research, published in Pediatrics, changes the conversation.

Key Findings: How Do They Compare?

The interim analysis, led by a team of pediatric researchers, examined outcomes in infants whose mothers received RSVpreF during pregnancy versus those who received nirsevimab as infants. While the study is still ongoing, early results suggest:

• Maternal vaccination: Reduced the risk of RSV-related hospitalization by approximately 50% in the first months of life, with protection lasting through the first RSV season.
• Infant nirsevimab: Cut hospitalization risk by about 75% in the first few months after administration, though its protection wanes after the initial RSV season.
• Combined approach: The study hints at potential synergistic effects when both strategies are used together, though long-term data is still needed.

Why the difference? Maternal vaccination provides passive immunity through placental transfer, offering early protection that aligns with the timing of peak RSV risk. Nirsevimab, by contrast, delivers immediate but temporary defense, making it ideal for high-risk infants or those born during RSV season.

Expert Reactions: What the Debate Reveals

The study has drawn attention from pediatricians and public health officials, particularly around how these tools might be used in tandem. Dr. Maria Manzoni, a pediatric infectious disease specialist at University of Bonn, has been among the most vocal critics, questioning whether the data fully captures real-world variability in maternal antibody transfer or infant response to nirsevimab.

“While both interventions are valuable, their combined use raises logistical and ethical questions,” Manzoni noted in a recent commentary. “For instance, how do we ensure equitable access when maternal vaccination requires prenatal care infrastructure that isn’t available everywhere?”

The authors of the study acknowledge these challenges, emphasizing that their findings are preliminary. They call for further research to determine whether sequential administration—maternal vaccination followed by nirsevimab—could offer superior protection than either strategy alone.

What Parents Need to Know

For families planning pregnancies or caring for newborns, the study offers several takeaways:

• Timing matters: Maternal RSVpreF should be administered during late pregnancy (ideally between 24–36 weeks gestation) to allow antibodies to transfer to the fetus. CDC guidelines recommend vaccination for all pregnant individuals during RSV season.
• Nirsevimab is for infants: Given as a single injection, nirsevimab is approved for use in infants starting at birth, with the first dose recommended before the onset of RSV season. It’s particularly beneficial for premature infants or those with chronic lung disease.
• Combined protection may be optimal: While more data is needed, early signals suggest that using both strategies could provide layered defense—maternal antibodies for early protection and nirsevimab for sustained coverage.

Global Impact: Who Benefits Most?

RSV doesn’t discriminate by geography, but its burden falls hardest on low-income countries with limited healthcare access. The World Health Organization (WHO) has highlighted maternal RSV vaccination as a priority for global rollout, given its potential to reduce neonatal mortality in regions where infant immunization programs are underdeveloped.

“This study underscores the need for a two-pronged approach,” said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, in a recent address. “Maternal vaccination can be integrated into existing prenatal care, while nirsevimab offers a bridge for infants who may miss the window for maternal protection.”

However, cost remains a barrier. Nirsevimab, marketed as Beyfortus by AstraZeneca, carries a price tag of over $500 per dose in the U.S., raising concerns about affordability in lower-resource settings. Meanwhile, RSVpreF, developed by Pfizer, is priced at around $200 per dose, though pricing varies by country.

A Call for Further Research

The authors emphasize that their findings are interim and based on a subset of the full study population. Key questions remain unanswered:

• How long does combined protection last?
• Are there subgroups of infants who benefit more from one strategy over the other?
• What are the long-term safety profiles of sequential administration?

Ongoing trials, including a phase 3 study by the National Institute of Allergy and Infectious Diseases (NIAID), aim to address these gaps. Results are expected by late 2027.

What Happens Next?

As RSV season approaches in the Northern Hemisphere, parents and healthcare providers are left with more questions than answers. Here’s what to watch for:

• Regulatory updates: The FDA and EMA are expected to review additional data on combined strategies in the coming months. Updates will likely be posted on their official websites.
• Insurance coverage: Reimbursement policies for nirsevimab and RSVpreF are still evolving. The Centers for Medicare & Medicaid Services (CMS) recently expanded coverage for nirsevimab for high-risk infants, but maternal vaccination coverage varies by state.
• Global rollout: The WHO’s Strategic Advisory Group of Experts (SAGE) is reviewing recommendations for maternal RSV vaccination in low-income countries, with a decision expected by mid-2026.

Key Takeaways

• Maternal RSVpreF vaccination reduces RSV hospitalization risk by ~50% in infants.
• Infant nirsevimab cuts risk by ~75% but offers shorter-term protection.
• Combined strategies may provide layered defense, though more data is needed.
• Access and cost remain major barriers, particularly in low-resource settings.
• Parents should discuss options with their obstetricians or pediatricians based on individual risk factors.

Your Questions, Answered

Q: Should all pregnant women get the RSVpreF vaccine?

A: Current guidelines recommend vaccination for all pregnant individuals during RSV season, regardless of risk factors. However, individual decisions should be made in consultation with a healthcare provider.

Q: Is nirsevimab safe for all newborns?

A: Yes, nirsevimab is approved for use in all infants starting at birth. It has not been associated with serious side effects in clinical trials, though mild reactions like fever or injection-site irritation may occur.

Q: Can I give my baby nirsevimab if I didn’t get the maternal vaccine?

A: Absolutely. Nirsevimab is an independent strategy and can be used regardless of maternal vaccination status. The two approaches are complementary.

Q: Will insurance cover both vaccines?

A: Coverage varies. Many private insurers now cover nirsevimab for high-risk infants, and maternal RSVpreF is increasingly included in prenatal benefit packages. Medicaid policies differ by state—check with your provider for specifics.

Q: When will we know if combining both is safe?

A: Ongoing trials, including those sponsored by NIAID, aim to provide definitive answers by 2027. Until then, experts recommend discussing risks and benefits with your healthcare team.

The Bottom Line

RSV prevention is entering a new era, with maternal vaccination and infant immunization offering powerful tools to protect the youngest and most vulnerable. While questions remain about how best to combine these strategies, the science is clear: prevention works. For parents, the message is simple: Talk to your doctor about your options early—before the next RSV season arrives.

As we await further data, one thing is certain: The fight against RSV is no longer just about treatment. It’s about stopping the virus before it starts.

Have questions or personal experiences with RSV prevention? Share your thoughts in the comments below—or tag us on social media with #RSVPrevention.